Last reviewed · How we verify
NCT04354181
Urine Biomarker for Stone Recurrence
trial in Urolithiasis in 80 participants. Completed in 20 January 2023.
20 January 2023
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 24 July 2020 |
| Primary completion | 20 January 2023 |
| Estimated completion | 20 January 2023 |
| Sites | 1 location across Hong Kong |
Conditions studied
- Urolithiasis — all drugs for Urolithiasis →
Sponsor
Chinese University of Hong Kong
Who can join
Adults 18 to 100, any sex, with Urolithiasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite the advent of treating stones with Extracorporeal Shock Wave Lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL), the recurrence rate for renal stones remains high and this may be due to poor compliance of patients with dietary and fluid advice, age, metabolic abnormalities, medicines and the formation of "new stones" from clinically insignificant residual fragments (CIRF). Though some patients become stone-free after ESWL/PCNL or open surgeries, the majority develop "new stones" and it is difficult to predict when these stones will recur until either they have imaging perform or they developed symptoms. However, the use of regular imaging for monitoring will be costly and involve radiation exposure. Therefore, a diagnostic tool is needed to enable the clinician and/or patient to monitor for stone recurrence. In the previous studies, some urine markers were identified that are related to stone formation. The relationship of these urine markers with the recurrence of renal stone will be further explore in this study. Also, potential markers that could predict stone recurrence will be identified, and hence earlier intervention could be offered to patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04354181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urolithiasis
Currently open trials in the same condition.
- NCT07378904 — Sterile Water Injection vs Morphine for Renal Colic · NA · active not recruiting
- NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease · NA · recruiting
- NCT06651294 — Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments · NA · recruiting
- NCT07514676 — Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Cult · active not recruiting
- NCT06158620 — Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease · Phase 1, PHASE2 · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04354181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 10 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing